Ultragenyx Pharmaceutical Inc. (RARE)

NasdaqGS • Currently up 0.35 (+1.22%) in today's trading session

1 member of Congress has disclosed 4 trades in Ultragenyx Pharmaceutical Inc. (RARE) via STOCK Act filings. The most recent disclosure was a purchase by Gilbert Cisneros on 3 March 2026. Aggregate disclosed activity totals roughly $32K in purchases (midpoint estimates from bracketed disclosure amounts).

Ultragenyx Pharmaceutical Inc. is currently trading at $29.11, positioned at 45% of its 52-week range ($18.29 – $42.37).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$29.11
24h Change
+0.35 (+1.22%)
52 Week Range
$18.29—$42.37
View on NASDAQ

Ultragenyx Pharmaceutical Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for RARE

Select to highlight on chart
4 transactions
Compliance: 100%
Gilbert Cisneros3 Mar 20267 Apr 2026PurchaseStock$1,001 - $15,000+26.46%
Gilbert Cisneros18 Feb 20269 Mar 2026PurchaseStock$1,001 - $15,000+44.25%
Gilbert Cisneros8 Aug 202512 Sept 2025PurchaseStock$1,001 - $15,000+4.60%
Gilbert Cisneros15 Jul 202514 Aug 2025PurchaseStock$1,001 - $15,000-0.41%

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$2.89B

Volume

1.64M

Beta

0.38

P/E Ratio

-4.77

Fundamentals

EPS

$-6.10

Div. Yield

—

Open

$29.02

Day Range

$29.01 — $30.14

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Emil D. Kakkis
IPO Date
2014-01-31
Website
www.ultragenyx.com

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international...

Earnings

Next Report

Q2 2026

4 Aug

EPS Est.

$-1.24

Rev. Est.

$181.7M

Days Until

41

Recent Quarters

Q1 20265 May
EPS$-1.84
Miss 23.7%
Q4 202512 Feb
EPS$-1.29
Miss 7.5%
Q3 20254 Nov
EPS$-1.81
Miss 47.1%
Q2 20255 Aug
EPS$-1.17
Beat 7.9%
Q1 20256 May
EPS$-1.57
Miss 1.9%
Q4 202413 Feb
EPS$-1.39
Miss 5.3%
Q3 20245 Nov
EPS$-1.40
Beat 3.5%
Q2 20241 Aug
EPS$-1.52
Beat 7.3%
Q1 20242 May
EPS$-2.03
Miss 18.0%
Q4 202315 Feb
EPS$-1.52
Beat 7.9%
Q3 20232 Nov
EPS$-2.23
Miss 7.2%
Q2 20233 Aug
EPS$-2.25
Miss 6.6%
Q1 20234 May
EPS$-2.33
Miss 18.3%
Q4 202216 Feb
EPS$-2.16
Miss 6.4%
Q3 20222 Nov
EPS$-2.43
Miss 6.1%
Q2 202228 Jul
EPS$-2.26
Miss 31.4%
Q1 20225 May
EPS$-2.19
Miss 24.4%
Q4 202110 Feb
EPS$-1.79
Miss 35.6%
Q3 20212 Nov
EPS$-1.08
Beat 24.5%
Q2 20212 Aug
EPS$-1.45
Miss 13.3%
Q1 20214 May
EPS$-2.03
Miss 62.4%
Q4 202011 Feb
EPS$-1.34
Miss 26.4%
Q3 202027 Oct
EPS$-1.13
Beat 8.9%
Q2 202030 Jul
EPS$-0.82
Beat 47.4%
Q1 20206 May
EPS$-2.04
Miss 27.5%
Q4 201913 Feb
EPS$-1.64
Miss 1.9%
Q3 20195 Nov
EPS$-1.96
Miss 14.6%
Q2 20191 Aug
EPS$-1.72
Beat 0.6%
Q1 20196 May
EPS$-1.82
Miss 5.2%
Q4 201819 Feb
EPS$-1.73
Beat 0.6%
Q3 20185 Nov
EPS$-1.74
Beat 10.3%
Q2 20182 Aug
EPS$-1.87
Beat 10.9%
Q1 20187 May
EPS$0.62
Beat 203.3%
Q4 201720 Feb
EPS$-2.27
Miss 13.5%
Q3 20172 Nov
EPS$-1.87
Beat 0.0%
Q2 201727 Jul
EPS$-1.72
Beat 0.6%
Q1 20174 May
EPS$-1.63
Beat 4.1%
Q4 201616 Feb
EPS$-1.75
Miss 0.6%
Q3 20167 Nov
EPS$-1.64
Miss 7.2%
Q2 20168 Aug
EPS$-1.46
Beat 0.7%
Q1 20169 May
EPS$-1.35
Miss 4.7%
Q4 201525 Feb
EPS$-1.42
Miss 27.9%
Q3 20159 Nov
EPS$-1.03
Miss 21.2%
Q2 201513 Aug
EPS$-0.83
Miss 33.9%
Q1 201511 May
EPS$-0.63
Miss 16.7%
Q4 201425 Mar
EPS$-0.52
Beat 1.9%
Q3 201410 Nov
EPS$-0.50
Miss 11.1%
Q2 201411 Aug
EPS$-0.45
Miss 9.8%
Q1 201412 May
EPS$-0.85
Miss 123.7%
Q4 201324 Mar
EPS$-4.98
Miss 1210.5%
Q4 201324 Mar
EPS$-3.35
Q1 201330 Jun
EPS$-0.37
Q4 201231 Mar
EPS$-0.29
Q3 201231 Dec
EPS$-1.46

1 politician traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

AAPL

Apple Inc.

20
$293.17-1.13 (-0.38%)
Technology
Held by same politician
Significant holdings value
1 politician
View Stock

SPY

State Street SPDR S&P 500 ETF Trust

17
$733.30-0.28 (-0.04%)
Financial Services
Held by same politician
1 politician
View Stock

WBI

WaterBridge Infrastructure LLC

17
$28.30-0.29 (-1.01%)
Energy
Held by same politician
1 politician
View Stock

Frequently Asked Questions about RARE

Which members of Congress have traded RARE?
1 member of Congress has disclosed 4 trade in Ultragenyx Pharmaceutical Inc. (RARE) under the STOCK Act: Gilbert Cisneros.
When was RARE most recently disclosed by Congress?
The most recent RARE disclosure was a purchase by Gilbert Cisneros on 3 March 2026.
What is the total disclosed congressional trading volume for RARE?
Members of Congress have disclosed approximately $32K in RARE purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in RARE?
This RARE page updates as soon as new STOCK Act disclosures are filed for Ultragenyx Pharmaceutical Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
Follow on XJoin our Discord
PoliticiansBillsPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.